alpha-环己基-苯乙酸 2-(二乙基氨基)乙基酯 | 1679-76-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: alpha-环己基-苯乙酸 2-(二乙基氨基)乙基酯
• 中文别名: 促生定；六氢芬宁；alpha-环己基-苯乙酸2-(二乙基氨基)乙基酯；六氢解痉素
• 英文名称: drofenine
• 英文别名: (+/-)-Cyclohexyl-phenyl-essigsaeure-(2-diethylamino-ethylester)；2-(diethylamino)ethyl 2-cyclohexyl-2-phenylacetate
• CAS: 1679-76-1
• 化学式: C₂₀H₃₁NO₂
• 分子量: 317.472
• InChiKey: AGJBLWCLQCKRJP-UHFFFAOYSA-N

物化性质

• 沸点：
  bp0.15 158°
• 密度：
  1.0047 g/cm3

计算性质

• 辛醇/水分配系数(LogP)：
  5.3
• 重原子数：
  23
• 可旋转键数：
  9
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.65
• 拓扑面积：
  29.5
• 氢给体数：
  0
• 氢受体数：
  3

安全信息

• 海关编码：
  2922199090

反应信息

• 作为反应物：
  描述：

  alpha-环己基-苯乙酸 2-(二乙基氨基)乙基酯 、 溴甲苯 在 乙醚 作用下， 生成 diethyl-benzyl-[2-(cyclohexyl-phenyl-acetoxy)-ethyl]-ammonium; bromide
  参考文献：
  名称：

  Überdie Darstellung einiger承租人Ester替代Essigsäuren

  摘要：

  DOI：

  10.1002/hlca.19410240162
• 作为产物：
  描述：

  alkaline earth salt of/the/ methylsulfuric acid 在 溶剂黄146 、 铂 作用下， 生成 alpha-环己基-苯乙酸 2-(二乙基氨基)乙基酯
  参考文献：
  名称：

  Überdie Darstellung einiger承租人Ester替代Essigsäuren

  摘要：

  DOI：

  10.1002/hlca.19410240162

文献信息

• Basic esters and process of preparing same
  申请人：CIBA PHARM PROD INC

  公开号：US02265184A1

  公开（公告）日：1941-12-09

  532,943. Alkamine esters of disubstituted fatty acids. SOC. OF CHEMICAL INDUSTRY IN BASLE. Aug. 1, 1939, Nos. 22277 and 22278. Convention dates, Aug. 5, 1938 and June 20, 1939. [Class 2 (iii)] Di-alicyclic- or aryl-alicyclic-fatty acids are converted into their esters with amino-alcohols substituted in the amino group. Thus, the fatty acid or a reactive derivative thereof such as a halide, ester, anhydride or ketene, is reacted with the amino-alcohol ; or a reactive ester of the amino-alcohol is reacted with the fatty acid or salt thereof ; or the fatty acid or its reactive derivative may be combined with an alcohol containing a substituent, e.g. halogen, which is then replaced, on interaction with an amine by a substituted amino group. The products, which are useful therapeutically, may be converted into their quaternary salts. According to the examples, (1) dicyclohexylacetic acid 2-diethylamino-ethanol ester is prepared by reacting the acid chloride, prepared from the acid by means of thionyl chloride, with the amino-alcohol; its bromethylate is formed by heating with alkyl bromide and its bromomethylate, bromethylate and bromobenzylate are similarly prepared ; (2) phenyl-cyclohexylacetic acid is heated with chlorethyldiethylamine in the presence or absence of potassium carbonate to give the diethylamino-ethanol ester, which may be converted into its bromomethylate by treatment with methyl bromide ; the same esters of phenyl-cyclohexyl-propionic, phenyl - cyclohexyl - butyric, dicyclopentyl acetic, phenyl-cyclopentyl-acetic, phenyl-#<;SP>;1<;/SP>;- or #<;SP>;2<;/SP>;-cyclohexamyl-acetic and phenyl-#<;SP>;1<;/SP>;- or # <;SP>;2<;/SP>;-cyclopentenyl-acetic acids are similarly obtained ; also the piperidine-ethanol, diethylamino-n-butanol, diethylamino-ethanol, morpholino - ethanol, ethyl - acetoxyethylaminoethanol, ethyl-hydroxypropylamino-ethanol, methyl-propylamino-ethanol and m-dimethylaminocyclohexanol esters of phenyl-cyclohexylacetic acid. The following additional esters are referred to :-dicyclohexyl-acetic acid tropine ester, α:α<;SP>;1<;/SP>;-dicyclohexyl-α-hydroxyacetic acid diethylamino-ethanol ester, α-phenyl-α-cyclohexyl-α-hydroxyacetic acid diethylamino-ethanol ester, the phenyl-cyclohexyl-acetic acid esters of ecgonine methyl ester and phenyldimethylaminocyclohexyl-acetic acid diethylamino-ethanol ester. The Specification as open to inspection under Sect. 91 also describes the manufacture of alkamine esters of mono-alicyclic-fatty acids. Thus, cyclohexyl-acetic acid, prepared by reduction of phenylacetic acid with hydrogen in presence of platinum, is converted into its chloride by means of thionyl chloride and reacted with diethylamino-ethanol to give cyclohexylacetic acid diethylamino-ethanol ester. In analogous manner are prepared α-cyclohexylhydracrylic acid tropine and scopine esters (the acid is prepared by reduction of tropic acid with hydrogen in presence of platinum), α-cyclohexyl-α-propyl-acetic acid diethylaminoetbanol ester (the acid is obtained by hydrogenation of α-phenyl-α-propyl-acetic acid in presence of platinum), and cyclohexyl-diethylaminoethyl-acetic acid diethylamino-ethanol ester (the acid being prepared by reaction of phenylacetonitrile with diethylaminoethyl chloride in presence of sodamide, saponification of the nitrile and reduction of the product). Other acids that may be used are cyclohexenyl-fatty acids and hydronaphthalene-fatty acids. This subject-matter does not appear in the Specification as accepted. Di-alicyclic- and aryl-alicyclic-fatty acids. Phenyl-cyclohexyl-acetic acid is obtained by reaction of phenylacetonitrile with cyclohexyl bromide in presence of sodamide and saponification of the product. Similarly, by reaction of phenylacetonitrile with A , - or A 2-cyclohexenyl bromide, #<;SP>;1<;/SP>;- or # <;SP>;2<;/SP>;-cyclopentenyl bromide or dimethylaminocyclohexyl bromide, followed by saponification, the corresponding disubstituted acetic acids are obtained. Phenyl-cyclohexylpropionic and -butyric acids are prepared by reduction of an ester of diphenyl-propionic or - butyric acid with hydrogen in presence of a nickel catalyst, followed by saponification of the ester. Phenyl-cyclopentyl-acetic acid is obtained from a phenyl-cyclopentenyl-acetic acid by the action of mild reducing agents. α:α-Dicyclohexyl-α-hydroxyacetic acid results from the catalytic reduction of benzilic acid. α - Phenyl - x - cyclohexyl - α - hydroxyacetic acid is made by reacting a benzoyl-formic acid ester with cyclohexyl-magnesium bromide and saponifying the product. Di-alicyclic- and aryl-alicyclic-fatty acid anhydrides and -ketenes. The anhydrides are prepared by reacting an alkali metal salt of the acid with the corresponding acid halide, whilst the ketenes are formed when a di-alicyclic- or aryl-alicyclic-α-chlorofatty acid chloride, prepared by reacting the corresponding α-hydroxy acid with phosphorus pentachloride, is treated with zinc.

  532,943. 二取代脂肪酸的烷胺酯。巴塞尔化学工业协会。1939年8月1日，编号22277和22278。会议日期，1938年8月5日和1939年6月20日。[2（iii）类]二脂环或芳基脂环脂肪酸与氨基醇在氨基上取代的酯转化为它们的酯。因此，脂肪酸或其反应衍生物，如卤化物、酯、酸酐或酮，与氨基醇反应；或者氨基醇的反应酯与脂肪酸或其盐反应；或者脂肪酸或其反应衍生物可以与含有取代基（例如卤素）的醇结合，然后通过与胺作用替换为取代的氨基。这些在治疗上有用的产品可以转化为它们的季铵盐。根据示例，（1）二环己基乙酸2-二乙基氨基乙醇酯是通过将酸氯与氨基醇反应制备的，该酸氯是通过用亚砜氯制备的酸制备的；它的溴甲基酸酯通过与溴代烷反应形成，其溴甲基酸酯、溴乙酸酯和溴苄酸酯类似制备；（2）苯基环己基乙酸与氯乙基二乙胺在存在或不存在碳酸钾的情况下加热，得到二乙基氨基乙醇酯，可以通过与溴甲烷处理转化为其溴甲基酸酯；苯基环己基丙酸、苯基-环己基-丁酸、二环戊基乙酸、苯基-环戊基-乙酸、苯基-#<;SP>;1<;/SP>;-或#<;SP>;2<;/SP>;-环己基-乙酸和苯基-#<;SP>;1<;/SP>;-或#<;SP>;2<;/SP>;-环戊烯基-乙酸的相同酯也类似获得；还有苯基环己基乙酸的哌啶-乙醇、二乙基氨基正丁醇、二乙基氨基乙醇、吗啉-乙醇、乙基-乙酰氧乙基氨基乙醇、乙基-羟丙基氨基乙醇、甲基-丙基氨基乙醇和苯基环己基乙酸的m-二甲基氨基环己醇酯。还提到以下额外的酯：二环己基乙酸曲马多酯，α:α<;SP>;1<;/SP>;-二环己基-α-羟基乙酸二乙基氨基乙醇酯，α-苯基-α-环己基-α-羟基乙酸二乙基氨基乙醇酯，苯基-环己基乙酸酯的可卡因甲酯和苯基二甲基氨基环己基乙酸二乙基氨基乙醇酯。根据第91节开放检查的规范还描述了单脂环脂肪酸的烷胺酯的制备。因此，通过在铂存在下用氢还原苯乙酸制备环己基乙酸，将其氯化为环己基乙酸二乙基氨基乙醇酯。类似地，α-环己基羟基丙酸曲马多和斯科平酯（该酸通过在铂存在下用氢还原曲马酸制备）；α-环己基-α-丙基乙酸二乙基氨基乙醇酯（该酸通过在铂存在下用氢还原α-苯基-α-丙基乙酸制备），以及环己基-二乙基氨基乙基乙酸二乙基氨基乙醇酯（该酸通过苯乙腈与二乙基氨基乙基氯在苏打胺存在下反应，腈的皂化和产物的还原制备）。其他可能使用的酸是环己烯基脂肪酸和氢化萘脂肪酸。这个主题在接受的规范中没有出现。二脂环和芳基脂环脂肪酸。苯基环己基乙酸是通过苯乙腈与环己基溴在苏打胺存在下反应并皂化产物制备的。类似地，通过苯乙腈与A ，-或A 2-环己烯基溴、#<;SP>;1<;/SP>;-或#<;SP>;2<;/SP>;-环戊烯基溴或二甲基氨基环己基溴反应，然后皂化，得到相应的二取代乙酸。苯基环己基丙酸和-丁酸是通过在镍催化剂存在下用氢还原二苯基-丙酸或-丁酸酯，然后皂化酯制备的。苯基环戊基乙酸是通过温和还原剂作用于苯基环戊烯基乙酸制备的。α:α-二环己基-α-羟基乙酸是通过苯甲酸酮催化还原得到的。α-苯基-x-环己基-α-羟基乙酸是通过苯甲酸酯与环己基溴镁反应并皂化产物制备的。二脂环和芳基脂环脂肪酸酸酐和酮。酸酐是通过将酸的碱金属盐与相应的酸卤化物反应制备的，而当通过将相应的α-羟基酸与五氯化磷反应制备的二脂环或芳基脂环-α-氯脂肪酸氯化物与锌处理时，形成酮。
• Hydroxylated nebivolol metabolites
  申请人：O'Donnell P. John

  公开号：US20070014733A1

  公开（公告）日：2007-01-18

  Hydroxylated nebivolol metabolites increase NO release from human endothelial cell preparations in a concentration dependent fashion following acute administration. In addition, hydroxylated nebivolol metabolites, including but not limited to 4-hydroxy-6,6′difluoro-, 4-hydroxy-5-phenol-6,6′difluoro-, and 4-hydroxy-8-pheno-6,6′difluoro-, have the ability to increase the capacity for NO release in human endothelial cells following chronic administration. This invention provides hydroxylated nebivolol metabolites and compositions comprising nebivolol and/or at least one hydroxylated metabolite of nebivolol and/or at least one additional compound used to treat cardiovascular diseases or a pharmaceutically acceptable salt thereof. In addition, this invention provides methods of treating and/or preventing vascular diseases by administering at least one hydroxylated metabolite of nebivolol that is capable of releasing a therapeutically effective amount of nitric oxide to a targeted site affected by the vascular disease. Also, this invention is directed to the treatment and/or prevention of migraine headaches administering at least one hydroxylated metabolite of nebivolol. This invention may also be used in conjunction with or as a single treatment of metabolic syndrome disorders.

  羟基化奈必洛尔代谢物在急性给药后以浓度依赖性方式增加人内皮细胞制剂的一氧化氮释放。此外，羟基化奈必洛尔代谢物，包括但不限于4-羟基-6,6'-二氟代-、4-羟基-5-苯酚-6,6'-二氟代-和4-羟基-8-苯并-6,6'-二氟代-，在慢性给药后能够增加人内皮细胞的一氧化氮释放能力。本发明提供了羟基化奈必洛尔代谢物和包含奈必洛尔和/或至少一种羟基化奈必洛尔代谢物和/或至少一种用于治疗心血管疾病的附加化合物的组合物，以及可药用的盐。此外，本发明还提供了通过给药至少一种能够释放治疗有效量的一氧化氮到受血管疾病影响的靶向部位的羟基化奈必洛尔代谢物来治疗和/或预防血管疾病的方法。本发明还涉及通过给药至少一种羟基化奈必洛尔代谢物来治疗和/或预防偏头痛。本发明还可以与治疗代谢综合征障碍的其他治疗联合使用，或作为单一治疗。
• METHODS AND COMPOSITIONS FOR TREATING INFECTION
  申请人：UNIVERSITY OF ROCHESTER

  公开号：US20150238473A1

  公开（公告）日：2015-08-27

  Provided herein are compositions and methods for treating or preventing infection.

  本文提供了用于治疗或预防感染的组合物和方法。
• Glucuronidated nebivolol metabolites
  申请人：O'Donnell P. John

  公开号：US20070014734A1

  公开（公告）日：2007-01-18

  This invention provides glucuronidated nebivolol metabolites and pharmaceutical compositions of glucuronidated nebivolol metabolites for treatment of cardiovascular diseases. In addition, this invention also provides compositions comprising nebivolol and/or at least one glucuronidated metabolite of nebivolol and/or at least one other active compound in a pharmaceutically acceptable carrier. This invention also provides methods of treating and/or preventing vascular diseases, by administering at least one glucuronidated metabolite of nebivolol that is capable of releasing a therapeutically effective amount of nitric oxide to a targeted site affected by the vascular disease. Also, this invention is directed to the treatment and/or prevention of migraine headaches administering at least one glucuronidated metabolite of nebivolol. This invention may also be used in conjunction with or as a single treatment of metabolic syndrome disorders.

  这项发明提供了葡萄糖醛酸化的尼布ivolol代谢物以及用于治疗心血管疾病的葡萄糖醛酸化的尼布ivolol代谢物的制药组合物。此外，该发明还提供了包含尼布ivolol和/或至少一种尼布ivolol的葡萄糖醛酸化代谢物和/或至少一种其他活性化合物的药用可接受载体的组合物。该发明还提供了通过向受影响血管疾病的靶位点投与至少一种能释放治疗有效量一氧化氮的尼布ivolol的葡萄糖醛酸化代谢物来治疗和/或预防血管疾病的方法。此外，该发明旨在通过投与至少一种尼布ivolol的葡萄糖醛酸化代谢物来治疗和/或预防偏头痛。该发明还可与代谢综合征紊乱的单一治疗或联合治疗一起使用。
• Technology for the Preparation of Microparticles
  申请人：Malakhov Michael

  公开号：US20090098207A1

  公开（公告）日：2009-04-16

  Microspheres are produced by contacting a solution of a macromolecule or small molecule in a solvent with an antisolvent and a counterion, and chilling the solution. The microspheres are useful for preparing pharmaceuticals, nutraceuticals, cosmetic products and the like of defined dimensions.

  微球是通过将溶液中的大分子或小分子与抗溶剂和对离子接触，并冷却溶液而制备的。这些微球可用于制备具有明确定义尺寸的药物、营养保健品、化妆品等产品。